HemoCath
HemoCath is an early-stage MedTech company pioneering innovations in Digital Medicine for critically ill patients and those with heart failure. Their flagship product, the Swan-HemoCath™ Critical Care AI Platform, combines a minimally-invasive HemoCath pulmonary artery catheter with the Swan AI Cloud™ (B2B AI/SaaS). This platform offers real-time, AI-powered hemodynamic monitoring, providing clinicians with actionable data to improve treatment decisions, enhance patient outcomes, reduce hospital stays, and lower healthcare costs. The HemoCath PA catheter is designed to be less invasive, more accurate, and easier to use than existing Gold Standard PA catheters. While not yet approved for clinical use, the company aims to advance critical care by providing next-generation hemodynamic monitoring solutions inspired by the legacy of Dr. Jeremy Swan.
HemoCath
HemoCath is an early-stage MedTech company pioneering innovations in Digital Medicine for critically ill patients and those with heart failure. Their flagship product, the Swan-HemoCath™ Critical Care AI Platform, combines a minimally-invasive HemoCath pulmonary artery catheter with the Swan AI Cloud™ (B2B AI/SaaS). This platform offers real-time, AI-powered hemodynamic monitoring, providing clinicians with actionable data to improve treatment decisions, enhance patient outcomes, reduce hospital stays, and lower healthcare costs. The HemoCath PA catheter is designed to be less invasive, more accurate, and easier to use than existing Gold Standard PA catheters. While not yet approved for clinical use, the company aims to advance critical care by providing next-generation hemodynamic monitoring solutions inspired by the legacy of Dr. Jeremy Swan.
TL;DR
Sector: MedTech / Digital Health (hemodynamic monitoring)
Flagship product: Swan-HemoCath PA catheter + Swan AI Cloud (HemoDynamix AI platform)
Clinical status: Not currently approved for clinical use
Founded: 2020
Team size (reported): 5 employees
Pre-seed round recorded (Apr 1, 2020); amount not disclosed
Company Overview
Problem Domain
Continuous hemodynamic monitoring in ICU and acute decompensated heart failure (ADHF).
Founded
2020
Industry
Medical devices; Digital health
Funding Track Record
Funding round recorded on Crunchbase; amount and investors not publicly disclosed.